Authors

Richard F. Cahill, JD
Latest Article

Expert shares tips for safeguarding your practice when using telehealth

Health care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.

Allen Jacob, MD
Latest Article

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Zeyad Schwen, MD

Schwen is a urologist at Cleveland Clinic Glickman Urological and Kidney Institute in Ohio.

Latest Article

The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy

"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.

John Parkinson
Latest Article

UTI vaccine shows efficacy, safety in men and women

"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.

Christopher J.D. Wallis, MD, PhD, FRCSC
Latest Article

Update on advanced imaging in prostate cancer

Advances allow for more accurate detection of metastatic disease.

Inga Shugalo
Latest Article

Medical software should be chosen based on your practice’s life cycle stage

At each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.

Daniel E. Spratt, MD
Latest Article

Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions

Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions.

Peter Fioramonti, BS

Fioramonti is a clinical research assistant with Associated Medical Professionals in Syracuse, New York.

Latest Article

Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma

"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.

Danielle Ternyila
Latest Article

Subgroup data sustain enzalutamide PFS benefit in nmCRPC

No new safety signals were reported with the androgen receptor pathway inhibitor.

Emory Urology
Latest Article

New study uncovers how prostate cancer becomes deadly and offers hope for new treatments

A first-of-its kind study led by Emory researchers uncovered how prostate cancer transforms into its most lethal form — and identified a promising new treatment strategy.

Ricardo Soares, MD

Dr. Soares is a urologist with Northwestern Medicine in Chicago (Western suburbs), Illinois.

Latest Article

Minimizing incontinence after radical prostatectomy: Lessons learned

"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.

Jesse D. Bracamonte, DO, FAAFP
Latest Article

Physician Commentary: Do EHR upgrades really enhance patient care?

"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.

Joelle Hamilton, MD
Latest Article

Case review: An incidentally discovered renal mass

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

Tim Kostner
Latest Article

Expert explains how to fully optimize EHRs

Recent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.

Ryan McDonald
Latest Article

Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinoma

The exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.

Lindsay Fischer
Latest Article

Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUC

The real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Jason Harris
Latest Article

Expert highlights the latest radiotherapy developments in prostate cancer

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

Caitlin Delaney, MD
Latest Article

Physician Burnout: Assessing and addressing its impact on your family

“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.

Silas Inman
Latest Article

Capivasertib prolongs rPFS in PTEN-deficient hormone-sensitive prostate cancer

"The primary end point was met, showing a statistically significant rPFS benefit with the combination of capivasertib and abiraterone," said Karim Fizazi, MD, PhD.

Amanda Wager, Esq
Latest Article

Malpractice Consult: Affidavits of merit and why they matter

Most states require affidavits for malpractice cases to proceed.

Christine Van Horn, MD
Latest Article

Quiz: Testicular trauma in 21-year-old

A 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.

Mark Schuster, MD, PhD
Latest Article

Expert emphasizes significance of physician self-care

If you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.

Urology Times contributor
Latest Article

A urologist on why the time is right to let go

"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.

Lisa F. Newcomb, PhD
Latest Article

Lisa F. Newcomb, PhD, on active surveillance for prostate cancer

"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the risk-benefit of PSA screening," says Lisa F. Newcomb, PhD.

Jaret Shook
Latest Article

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Tony Berberabe, MPH
Latest Article

Extended lymphadenectomy yields no additional benefit vs standard procedure for urothelial cancer

Extended lymph node dissection during radical cystectomy offered no additional overall survival or disease-free survival benefit vs standard lymph node dissection.

Jeremy D. Handel, MD
Latest Article

Case review: An incidentally discovered renal mass

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

Morgan Bayer
Latest Article

2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBC

Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.

Hayley Virgil
Latest Article

Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPC

The median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.

Sabrina Serani
Latest Article

Apalutamide combo hits high 2-year RFS rate in prostate cancer

Treatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.